Cancer Biology & Therapy (Dec 2022)

High tumor amplification burden is associated with TP53 mutations in the pan-cancer setting

  • Rushikesh S. Joshi,
  • Amelie Boichard,
  • Jacob J. Adashek,
  • Razelle Kurzrock

DOI
https://doi.org/10.1080/15384047.2022.2128608
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 6

Abstract

Read online

Next-generation sequencing data is fundamentally changing the clinical management of patients with cancer. The most frequent genomic alterations in malignancy are mutations and amplifications, with a subset of tumors having multiple amplifications – “amplificators”. We sought to understand the molecular correlates of high tumor amplification burden in a pan-cancer context. Using both national registries and a single-institution dataset, our results demonstrate that cancers with TP53 mutations (as compared to those with wild-type TP53) exhibited significantly higher tumor amplification burden across all datasets. Amplifications, generally associated with overexpression, may be potentially actionable secondary consequences of TP53 mutations.

Keywords